IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科
学科主题临床医学
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial
Hu, Zhihuang1,2; Cheng, Ying3; Zhang, Hongyu4; Zhou, Caicun5; Han, Baohui6; Zhang, Yiping7; Huang, Cheng8; Chang, Jianhua9; Song, Xiangqun10; Liang, Jun11; Liang, Houjie12; Bai, Chunxue13; Yu, Shiying14; Chen, Jia15; Wang, Jie16; Pan, Hongming17; Chitkara, Denesh K.18; Hille, Darcy A.18; Zhang, Li1,2
关键词Nausea Emesis Aprepitant Emetogenic chemotherapy Standard antiemetic treatment
刊名SUPPORTIVE CARE IN CANCER
2014-04-01
DOI10.1007/s00520-013-2043-9
22期:4页:979-987
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Health Care Sciences & Services ; Rehabilitation
资助者Merck Sharp &amp ; Dohme Corp., a subsidiary of Merck &amp ; Co., Inc., Whitehouse Station, NJ, USA ; Merck Sharp &amp ; Dohme Corp., a subsidiary of Merck &amp ; Co., Inc., Whitehouse Station, NJ, USA
研究领域[WOS]Oncology ; Health Care Sciences & Services ; Rehabilitation
关键词[WOS]MODERATELY EMETOGENIC CHEMOTHERAPY ; NEUROKININ-1 RECEPTOR ANTAGONIST ; ANTIEMETIC THERAPY ; MULTIPLE CYCLES ; INDUCED EMESIS ; POSTOPERATIVE NAUSEA ; GUIDELINE UPDATE ; DEXAMETHASONE ; METAANALYSIS ; ONCOLOGY
英文摘要

Aprepitant, an oral neurokinin-1 receptor antagonist, has demonstrated improved control of chemotherapy-induced nausea and vomiting (CINV) in previous studies. This is the first phase III study to evaluate the efficacy and tolerability of aprepitant in patients receiving highly emetogenic chemotherapy (HEC) in Asian countries.

This multicenter, double-blind, placebo-controlled trial assessed the prevention of CINV during the acute phase (AP), delayed phase (DP), and overall phase (OP). Patients receiving HEC were randomized to either an aprepitant group (day 1, aprepitant 125 mg; days 2-3, aprepitant 80 mg) or a standard therapy group (days 1-3, placebo). Both groups received intravenous granisetron and oral dexamethasone. The primary end point was complete response (CR; no emesis and no use of rescue therapy) during the OP.

Of the 421 randomized patients, 411 (98 %) were assessable for efficacy; 69.6 % (142/204) and 57.0 % (118/207) of patients reported CR during the OP in the aprepitant and standard therapy groups, respectively (P = 0.007). CR rates in the aprepitant group were higher during the DP (74.0 % vs. 59.4 %, P = 0.001) but were similar during the AP (79.4 % vs. 79.3 %, P = 0.942). Toxicity and adverse events were comparable in both groups.

The addition of aprepitant to standard antiemetic treatment regimens for Chinese patients undergoing HEC provided superior CINV prevention and was well tolerated.

语种英语
资助者Merck Sharp &amp ; Dohme Corp., a subsidiary of Merck &amp ; Co., Inc., Whitehouse Station, NJ, USA ; Merck Sharp &amp ; Dohme Corp., a subsidiary of Merck &amp ; Co., Inc., Whitehouse Station, NJ, USA
WOS记录号WOS:000332505800016
Citation statistics
Cited Times:14[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64769
Collection北京大学临床肿瘤学院_胸部肿瘤内科
作者单位1.Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
2.Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
3.Jilin Prov Canc Hosp, Dept Internal Med 1, Changchun, Peoples R China
4.Sun Yat Sen Univ, Dept Oncol, Affiliated Hosp 1, Zhuhai, Peoples R China
5.Tongji Univ, Shanghai Pulm Hosp, Inst Canc, Dept Oncol,Med Sch, Shanghai 200433, Peoples R China
6.Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai 200030, Peoples R China
7.Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou 310022, Zhejiang, Peoples R China
8.Fujian Med Univ, Dept Med Oncol, Fujian Prov Canc Hosp, Teaching Hosp, Fuzhou, Peoples R China
9.Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
10.Guangxi Zhuang Autonomous Reg Tumor Hosp, Dept Chemotherapy, Nanning, Peoples R China
11.Qingdao Univ, Dept Med Oncol, Affiliated Hosp, Coll Med, Qingdao 266071, Peoples R China
12.Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China
13.Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai 200032, Peoples R China
14.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Ctr Canc, Wuhan 430030, Hubei, Peoples R China
15.Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA
16.Jiangsu Canc Hosp, Dept Med Oncol, Nanjing 210009, Jiangsu, Peoples R China
17.Beijing Canc Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China
18.Zhejiang Univ, Dept Med Oncol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
Recommended Citation
GB/T 7714
Hu, Zhihuang,Cheng, Ying,Zhang, Hongyu,et al. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial[J]. SUPPORTIVE CARE IN CANCER,2014,22(4):979-987.
APA Hu, Zhihuang.,Cheng, Ying.,Zhang, Hongyu.,Zhou, Caicun.,Han, Baohui.,...&Zhang, Li.(2014).Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.SUPPORTIVE CARE IN CANCER,22(4),979-987.
MLA Hu, Zhihuang,et al."Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial".SUPPORTIVE CARE IN CANCER 22.4(2014):979-987.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Hu, Zhihuang]'s Articles
[Cheng, Ying]'s Articles
[Zhang, Hongyu]'s Articles
百度学术
百度学术Similar articles in
[Hu, Zhihuang]'s Articles
[Cheng, Ying]'s Articles
[Zhang, Hongyu]'s Articles
必应学术
必应学术Similar articles in
[Hu, Zhihuang]'s Articles
[Cheng, Ying]'s Articles
[Zhang, Hongyu]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.